As of the most recent data (September 2025), HELP shows a receivables of $4.7M. That compares with $5.5M in the prior-year period — down 14.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, HELP's receivables is now $4.7M (was $5.5M) — a 14.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Helus Pharma is outperforming or lagging.

Tracking HELP's receivables over time shows whether Helus Pharma is scaling, shrinking, or reshaping that part of the business. The current reading is $4.7M That compares with $5.5M in the prior-year period — down 14.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Helus Pharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $4.7M) with ownership activity and broader fundamentals.

Helus Pharma's receivables is $4.7M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.